1-acetyl-3,2-toluyl-5-fluorouracil has been researched along with fluorouracil in 5 studies
*Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. [MeSH]
*Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. [MeSH]
| Studies (1-acetyl-3,2-toluyl-5-fluorouracil) | Trials (1-acetyl-3,2-toluyl-5-fluorouracil) | Recent Studies (post-2010) (1-acetyl-3,2-toluyl-5-fluorouracil) | Studies (fluorouracil) | Trials (fluorouracil) | Recent Studies (post-2010) (fluorouracil) |
|---|---|---|---|---|---|
| 5 | 1 | 0 | 45,562 | 9,307 | 14,663 |
| Protein | Taxonomy | 1-acetyl-3,2-toluyl-5-fluorouracil (IC50) | fluorouracil (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.32 | |
| Thymidylate synthase | Mus musculus (house mouse) | 1.58 | |
| Aromatase | Homo sapiens (human) | 0.63 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukawa, K; Haga, S; Hiiragi, M; Irino, O; Kametani, T; Kigasawa, K; Nagamatsu, Y; Nakayama, M; Nishimura, N; Okada, T; Sugi, H; Taguchi, A; Wakisaka, K; Yamamoto, T | 1 |
| Okada, T; Yamajo, R; Yata, N | 1 |
| Feng, FY; Han, J; Li, L; Li, Q; Sui, GJ; Wang, PH; Zhang, Y; Zhang, YC; Zhang, ZH; Zhou, MZ; Zhu, YG | 1 |
| Chen, MH; Cui, SX; Gai, RY; Liu, J; Makuuchi, M; Qu, XJ; Tang, W; Wang, RH; Xu, WF; Yuan, YX; Zhou, Y | 1 |
| Chen, MH; Cheng, YN; Cui, SX; Li, X; Liu, J; Makuuchi, M; Qu, XJ; Tang, W; Tian, ZG; Xu, WF | 1 |
1 trial(s) available for 1-acetyl-3,2-toluyl-5-fluorouracil and fluorouracil
| Article | Year |
|---|---|
[Phase III clinical study of a new anticancer drug atofluding].
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Female; Fluorouracil; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocytopenia; Treatment Outcome | 2002 |
4 other study(ies) available for 1-acetyl-3,2-toluyl-5-fluorouracil and fluorouracil
| Article | Year |
|---|---|
Studies on the synthesis of chemotherapeutics. 10. Synthesis and antitumor activity of N-acyl- and N-(alkoxycarbonyl)-5-fluorouracil derivatives.
Topics: Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Female; Fluorouracil; Lethal Dose 50; Leukemia P388; Mice; Neoplasms, Experimental | 1980 |
Anti-tumor activity of 1-acetyl-3-o-toluyl-5-fluorouracil against murine hepatoma MH134 and its effects on tissue weights following subcutaneous and oral administration.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Female; Fluorouracil; Injections, Subcutaneous; Liver Neoplasms, Experimental; Mice; Mice, Inbred C3H; Organ Size; Spleen; Thymus Gland | 1985 |
Inhibition of human gastric carcinoma cell growth by atofluding derivative N3-o-toluyl-fluorouracil.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Liver; Male; Mice; Mice, Nude; Rats; Rats, Sprague-Dawley; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2006 |
Inhibition of human gastric carcinoma cell growth by treatment of N(3)-o-toluyl-fluorouracil as a precursor of 5-fluorouracil.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; In Situ Nick-End Labeling; Mice; Mice, Nude; Microsomes, Liver; Prodrugs; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2007 |